Treatment with Interferon alpha prior to discontinuation of Imatinib in patients with chronic myeloid leukemia

Cytokine

Volumn 57, Issue 2, 2012, Pages 290-293

  Hardan, Izhar ^a   Stanevsky, Anfisa ^a   Volchek, Yuliya ^a   Tohami, Tali ^a   Amariglio, Ninette ^a   Trakhtenbrot, Luba ^a   Koren Michowitz, Maya ^a   Shimoni, Avichai ^a   Nagler, Arnon ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

CML; IFN ; Imatinib; Stopping

Indexed keywords

BCR ABL PROTEIN; CYTARABINE; HYDROXYUREA; IMATINIB; PEGINTERFERON ALPHA2A;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BCR ABL GENE; CANCER REGRESSION; CANCER RELAPSE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOGENETICS; DRUG WITHDRAWAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE; HUMAN; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; DEMOGRAPHY; FEMALE; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84855449982     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.11.018     Document Type: Article

References (24)

1. Druker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
2. Hughes T.P., Kaeda J., Branford S., et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003, 49:1423-1432.
3. Branford S., Seymour J.F., Grigg A., et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 2007, 13:7080-7085.
4. Mahon F.X., Rea D., Guilhot J., et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010, 11:1029-1035.
5. Goh H.G., Kim Y.J., Kim D.W., et al. Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy. Leuk Lymphoma 2009, 50:944-951.
6. Kuwabara A., Babb A., Ibrahim A., et al. Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response. Blood 2010, 116:1014-1016.
7. Giles F.J., O'Dwyer M., Swords R. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2009, 23:1698-1707.
8. Kiguchi T., Tauchi T., Ito Y., Miyazawa K., Kimura Y., Ohyashiki K. Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase. Leuk Res 2009, 33:506-508.
9. Kantarjian H.M., O'Brien S., Cortes J.E., et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003, 97:1033-1041.
10. Mahon F.X., Delbrel X., Cony-Makhoul P., et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol 2002, 20:214-220.
11. Rousselot P., Huguet F., Rea D., et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2years. Blood 2007, 109:58-60.
12. Burchert A., Muller M.C., Kostrewa P., et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 2010, 28:1429-1435.
13. Simonsson B., Gedde-Dahl T., Markevarn B., et al. Combination of pegylated interferon-{alpha} 2b with imatinib increases molecular response rates in patients with low or combination of pegylated interferon-{alpha} 2b with imatinib increases molecular response rates in patients with low or intermediate risk chronic myeloid leukemia. Blood 2011, [Epub ahead of print].
14. Hughes T., Deininger M., Hochhaus A., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006, 108:28-37.
15. Kano Y., Akutsu M., Tsunoda S., et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001, 97:1999-2007.
16. Burchert A., Neubauer A. Interferon alpha and T-cell responses in chronic myeloid leukemia. Leuk Lymphoma 2005, 46:167-175.
17. Molldrem J.J., Lee P.P., Wang C., et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000, 6:1018-1023.
18. Nagler A., Ackerstein A., Barak V., Slavin S. Treatment of chronic myelogenous leukemia with recombinant human interleukin-2 and interferon-alpha 2a. J Hematother 1994, 3:75-82.
19. Jiang X., Zhao Y., Smith C., et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007, 21:926-935.
20. Essers M.A., Offner S., Blanco-Bose W.E., et al. IFN alpha activates dormant haematopoietic stem cells in vivo. Nature 2009, 458:904-908.
21. Mahon F.-X., Fort M.-P., Etienne G., et al. Interferon alpha alone is able to cure chronic myeloid leukemia in a small subset of patients despite the persistence of leukemic cells: experience of long follow up after treatment discontinuation. ASH Annual Meeting Abstracts 2010, 116:2299.
22. Saglio G., Kim D.-W., Issaragrisil S., et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362:2251-2259.
23. Kantarjian H., Shah N.P., Hochhaus A., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362:2260-2270.
24. Kantarjian H., Hochhaus A., Saglio G., et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukemia: 24-month minimum follow-up of the phase 3 randomized ENESTnd trial. Lancet Oncol 2011, 12:841-851.